46.52 USD
▲-2.55+3.38%
盘后 45.00 0.00%
2026-08-03
市值
$2.17B
市盈率
—
EPS
-75.36
股息率
—
52 周区间
23.00 – 52.15
成交量
484.69K
Beta
—
目标价
50.00
52W 低 23.0052W 高 52.15
价格走势
公司简介
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale...